Table of contents
September 2006 Volume 3 No 9
Editorial
Viewpoint
Genetic testing in cardiac disease: from bench to bedside
462Although genetic testing for hypertrophic cardiomyopathy and long QT syndrome is now clinically available, are we ready to reap the practical benefits of these molecular discoveries? How can genetic testing for heritable cardiovascular disorders improve the care of our patients now and in the future? As Allison Cirino and Carolyn Ho outline in this month's Viewpoint, the best is yet to come for genetic testing in cardiac disease.
Research Highlights
Patent foramen ovale is a marker of carcinoid heart disease progression
464doi:10.1038/ncpcardio0614 | Full Text | PDF (100K)
Case–control association study reveals genes involved in early-onset myocardial infarction
464Platelet expression of MRP-14 increases prior to STEMI
464Evidence for statin-mediated functions independent of lipid lowering
465doi:10.1038/ncpcardio0617 | Full Text | PDF (100K)
Community study shows shift in distribution of mortality from cardiovascular disease
465Role of tenascin-C in heart muscle after acute myocardial infarction
466doi:10.1038/ncpcardio0619 | Full Text | PDF (102K)
Transvenous leads increase thromboembolic risk in patients with intracardiac shunts
466Management of patients with LV dysfunction needing permanent ventricular pacing support
467doi:10.1038/ncpcardio0621 | Full Text | PDF (101K)
Blood pressure and cardiovascular outcomes in high-risk Hispanics
467Complex atherosclerotic aortic debris is not a risk factor for cryptogenic stroke
468Evidence for poor risk stratification in thromboprophylaxis for VTE
468Diagnosis of carotid artery stenosis by noninvasive imaging
468Disparities in stroke incidence and risk factors among elderly people in the US
469doi:10.1038/ncpneuro0256 | Full Text | PDF (100K)
Practice Points
Can microvolt T-wave alternans predict mortality in patients with ischemic cardiomyopathy?
470doi:10.1038/ncpcardio0636 | Full Text | PDF (100K)
Does the combination of stress perfusion and delayed-enhancement MRI improve the detection of CAD?
472doi:10.1038/ncpcardio0637 | Full Text | PDF (100K)
OASIS-5: how do fondaparinux and enoxaparin compare in patients with acute coronary syndromes?
474doi:10.1038/ncpcardio0639 | Full Text | PDF (101K)
Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation?
476doi:10.1038/ncpcardio0633 | Full Text | PDF (100K)
OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?
478doi:10.1038/ncpcardio0635 | Full Text | PDF (101K)
Reviews
Genetic determinants of the metabolic syndrome
482A single definition for the metabolic syndrome is not forthcoming since discussion of its forms and causes is continuing. Genetic causes and onset of the syndrome in relation to triggering genetic–environment interactions have been suggested. In this Review, the currently available knowledge about the most common purported genetic causes is drawn together.
doi:10.1038/ncpcardio0638 | Full Text | PDF (171K)
Modification of myocardial substrate use as a therapy for heart failure
490In healthy adult hearts approximately 70% of energy is obtained from fatty acids; the balance comes from lactate, pyruvate and ketones. The pattern of substrate use is altered in failing hearts. This Review discusses substrate use and the possible benefits of using metabolic agents to cause a shift away from fatty acids as the main substrate.
doi:10.1038/ncpcardio0583 | Full Text | PDF (220K)
No-reflow phenomenon and prognosis in patients with acute myocardial infarction
499In the no-reflow phenomenon, blood flow to an infarcted area can be markedly reduced by destruction of the microvasculature or blockage of vessels by microemboli, despite an open infarct-related artery. Minimization of the affected area is important to improve outcomes. Data are presented in this Review on causes and therapies.
doi:10.1038/ncpcardio0632 | Full Text | PDF (242K)
Surgery Insight: surgical methods to reverse left ventricular remodeling
507The severity of left ventricular dilatation and remodeling represents one of the strongest predictors of mortality. Prevention, reversal, or both of left ventricular remodeling therefore constitute crucial parts of therapy in many cases. Along with pharmacologic therapies various surgical procedures are available. In this Review, the most common surgical options for left ventricular remodeling are discussed.
doi:10.1038/ncpcardio0631 | Full Text | PDF (239K)
Case Study
Management of a case of peripartum cardiomyopathy
514doi:10.1038/ncpcardio0640 | Full Text | PDF (131K)
